التفاصيل البيبلوغرافية
| العنوان: |
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. |
| المؤلفون: |
Goldsmith, David1 CKD-MBD@era-edta.org, Covic, Adrian2, Vervloet, Marc3,4, Cozzolino, Mario5, Nistor, Ionut2,6 |
| المصدر: |
Nephrology Dialysis Transplantation. May2015, Vol. 30 Issue 5, p698-700. 3p. |
| مصطلحات موضوعية: |
*KIDNEY diseases, *BIOCHEMICAL research, *HYPERPARATHYROIDISM, *CALCIUM, *META-analysis, *PATIENTS, *THERAPEUTICS |
| مستخلص: |
This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERAEDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder